ALBIREO PHARMA INC's ticker is ALBO and the CUSIP is 01345P106. A total of 69 filers reported holding ALBIREO PHARMA INC in Q2 2018. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $1,938 | -99.9% | 89,683 | -35.8% | 0.00% | -25.0% |
| Q3 2022 | $2,704,000 | +598.7% | 139,683 | +616.3% | 0.00% | – |
| Q2 2022 | $387,000 | +35.3% | 19,500 | +103.1% | 0.00% | – |
| Q1 2022 | $286,000 | -13.3% | 9,600 | -6.3% | 0.00% | – |
| Q2 2019 | $330,000 | -58.1% | 10,248 | -58.1% | 0.00% | -100.0% |
| Q1 2019 | $787,000 | -15.0% | 24,448 | -35.2% | 0.00% | 0.0% |
| Q4 2018 | $926,000 | -33.3% | 37,732 | -10.4% | 0.00% | 0.0% |
| Q3 2018 | $1,389,000 | -79.6% | 42,132 | -78.9% | 0.00% | -75.0% |
| Q2 2018 | $6,822,000 | +126.6% | 199,798 | +116.2% | 0.00% | +33.3% |
| Q1 2018 | $3,011,000 | -2.6% | 92,432 | -23.4% | 0.00% | 0.0% |
| Q4 2017 | $3,091,000 | +8.9% | 120,732 | -10.9% | 0.00% | 0.0% |
| Q3 2017 | $2,839,000 | -5.2% | 135,532 | -6.8% | 0.00% | -25.0% |
| Q2 2017 | $2,996,000 | -16.6% | 145,432 | -2.8% | 0.00% | -20.0% |
| Q1 2017 | $3,591,000 | +36.1% | 149,632 | +0.5% | 0.01% | +25.0% |
| Q4 2016 | $2,639,000 | – | 148,838 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Prosight Management, LP | 480,000 | $14,318,000 | 9.25% |
| Decheng Capital Management III (Cayman), LLC | 518,342 | $15,462,000 | 4.74% |
| TANG CAPITAL MANAGEMENT LLC | 467,702 | $13,952,000 | 2.79% |
| Birchview Capital, LP | 113,000 | $3,371,000 | 2.43% |
| Privium Fund Management B.V. | 351,805 | $10,494,000 | 2.32% |
| Sio Capital Management, LLC | 144,546 | $4,312,000 | 1.43% |
| Perceptive Advisors | 2,360,139 | $70,403,000 | 1.41% |
| Chicago Capital, LLC | 1,011,744 | $30,180,000 | 1.30% |
| Endurant Capital Management LP | 120,834 | $3,604,000 | 0.95% |
| Nicholas Investment Partners, LP | 439,235 | $13,102,000 | 0.93% |